Scientific Research Publishing

Open Journal of Ophthalmology, 2025, 15(4), 177-191
https://www.scirp.org/journal/ojoph
ISSN Online: 2165-7416
ISSN Print: 2165-7408

Ocular & Otolaryngology Complications Following Botulinum Toxin and Dermal Filler Injections

Hannah Cobb[1], Natasha Doshi[2], Komalpreet Kaur[1], Alejandra Sataray-Rodriguez[3], Jessica Lee[4], Samreen Shah[5]

[1]Edward via College of Osteopathic Medicine, Auburn, AL, USA
[2]Lake Erie College of Osteopathic Medicine, Bradenton, FL, USA
[3]Reno School of Medicine, University of Nevada, Reno, NV, USA
[4]Northeast Ohio Medical University, Rootstown, OH, USA
[5]Edward via College of Osteopathic Medicine, Monroe, LA, USA
Email: cobbhannah@gmail.com

How to cite this paper: Cobb, H., Doshi, N., Kaur, K., Sataray-Rodriguez, A., Lee, J. and Shah, S. (2025) Ocular & Otolaryngology Complications Following Botulinum Toxin and Dermal Filler Injections. *Open Journal of Ophthalmology*, **15**, 177-191.
https://doi.org/10.4236/ojoph.2025.154022

Received: August 7, 2025
Accepted: September 12, 2025
Published: September 15, 2025

Abstract

Cutaneous fillers and botulinum toxin are widely used in dermatology and cosmetic surgery to enhance facial features, treat functional disorders, and combat signs of aging. While generally considered safe, it's crucial to understand potential complications. This review aims to provide a comprehensive understanding of cutaneous fillers and botulinum toxin, focusing on facial complications, particularly those related to ocular and ear areas. The review discusses various types of cutaneous fillers, including hyaluronic acid (HA), calcium hydroxylapatite (CaHA), poly-L-lactic acid (PLLA), and polymethylmethacrylate (PMMA), highlighting their distinct properties and applications. Different types of botulinum toxin A, such as onabotulinumtoxinA, abobotulinumtoxinA, and incobotulinumtoxinA, are also examined. Potential complications, ranging from transient issues like swelling and bruising to more severe events like vascular occlusion, ptosis, diplopia, and optic neuropathy, are discussed. Preventative measures, including thorough anatomical knowledge, proper injection techniques, patient education, and the use of ultrasound imaging, are emphasized to minimize risks. The importance of recognizing early signs of complications and implementing timely interventions, such as hyaluronidase administration or hyperbaric oxygen therapy, is highlighted. A collaborative approach involving ophthalmologists, otolaryngologists, vascular surgeons, and dermatologists is crucial for optimizing patient safety and outcomes. The review underscores the need for ongoing training and adherence to evidence-based guidelines to ensure safe and effective cosmetic procedures.

Methods: A systematic literature review was conducted to investigate ocular and otolaryngological complications following injectable botulinum toxin and cutaneous filler procedures. A comprehensive search of relevant databases was performed, utilizing keywords such as "botulinum injections", "ptosis", "thrombosis", "cutaneous fillers", and "adverse events". Studies were selected based on their analysis of complication types, etiological factors, and proposed prevention methods within the specified anatomical regions. **Results:** The literature review revealed that ocular and otolaryngological complications following injectable botulinum toxin and cutaneous filler procedures are influenced by a complex interplay of factors. Iatrogenic causes, such as improper injection technique and inadequate anatomical knowledge, were frequently reported. Patient-related factors, including anatomical variations and pre-existing conditions, also contributed to adverse outcomes. Furthermore, the literature highlighted the role of product-related factors, such as filler type and injection volume, in the development of complications. **Conclusion:** In conclusion, the analysis emphasizes the imperative of a comprehensive research agenda to expand upon the diverse challenges increasing ocular and otolaryngological complications during injectable botulinum and cutaneous filler injections. The identified iatrogenic factors, including technique and anatomical knowledge, necessitate tailored interventions and techniques to enhance precision and reduce complications. This research agenda aims to inform healthcare practices and policies, ultimately improving the safety profile for patients undergoing facial cosmetic procedures.

Keywords

Botulism Injections, Adverse Events, Cutaneous Fillers, Thrombosis, Ptosis

1. Introduction

Cutaneous fillers and botox are prominent modalities used in dermatology and cosmetic surgery due to their ability to enhance facial features, treat functional disorders, combat age-related volume loss, create a sense of facial balancing, and prevent or reduce wrinkles and folds that occur due to repetitive facial movements. Cutaneous filler can be composed of a variety of different materials such as hyaluronic acid (HA), calcium hydroxylapatite, and polymethylmethacrylate [1]. In contrast, botulinum toxin, also known as botox, is a neurotoxin that creates a temporary sense of muscle paralysis by blocking acetylcholine release at the neuromuscular junction in order to prevent formation of wrinkles and create a smoother skin surface [2]. These treatments are generally considered safe and allow for physical facial enhancement or symptom improvement without use of cosmetic surgery or more invasive protocols [3]. Three types of botulinum toxin A include onabotulinumtoxinA, abobotulinumtoxinA, and incobotulinumtoxinA with each having different variations associated with differences in pharmacological activity and efficacy [4]. Other variations include prabotulinumtoxinA and daxibotuli-

numtoxinA with all of these formulations outperforming placebo in treatment of glabellar lines without significant differences from each other in adverse events [5]. In an effort to enhance facial aesthetics and functionality botulinum toxin and filler treatments are used; however, it is important to understand potential complications in order to achieve optimal results. This review aims to create a deeper understanding of cutaneous fillers and Botox, and facial complications that may result with a specific emphasis on ocular and ear-related complications. Transient complications like mild swelling to moderate effects are discussed to educate providers on potential complications and allow for deeper understanding of these issues like eye and eyelid disorders [6]. Complications are typically transient, however, providers can implement practices like demarcating areas on the face that are meant to be targeted in order to avoid the main adverse effects like eyelid ptosis, diplopia, eyebrow asymmetry, palpebral ectropion, and lagophthalmos [3]. Through well thought out patient selection, anatomical considerations with injection technique, and understanding of complication management safe usage of botulinum toxin and cutaneous filler treatment can be facilitated. New strategies, like ultrasound imaging, have been used to make administration of botulinum toxin more precise by allowing more profound visualization of surrounding anatomic structures [7]. Preventative measures to minimize risks and best practices for practitioners to create an environment where adverse effects are managed swiftly and effectively. This review aspires to connect the dots between clinical practices and research methods by establishing a multidisciplinary dialogue involving dermatology, ophthalmology, and otolaryngology. Additionally, new practices for safety and imaging considerations are explored.

2. Discussion

Over View of Cutaneous Fillers and Botulism Injections

The use of cutaneous fillers and Botox has become widespread, with various modalities available to address a range of aesthetic concerns. The popularity and interest in fillers has grown largely due to the ease and minimal invasiveness of administration when compared to surgical options. Injectable fillers are often administered into the skin or subcutaneously to smooth fine lines and restore the appearance of lost volume [8]. Fillers can be categorized by their longevity within tissue, with different types being classified as temporary, semi-permanent, or permanent [9]. Cutaneous fillers can also be categorized based on their composition, with the most common types being hyaluronic acid, collagen, calcium hydroxylapatite, poly-L-lactic acid, and polymethylmethacrylate fillers [8]. Hyaluronic acid (HA) fillers, such as Juvederm and Restylane, are commonly used because they offer immediate volumizing results and can be reversed using hyaluronidase, if needed [10]. However, HA fillers are temporary and often necessitate subsequent maintenance injections. Despite this, HA fillers have become a popular choice among injectors, while collagen fillers have declined in their usage. Collagen fillers are often formulated using animal-derived, or more specifically, bovine

collagen, which runs the risk of causing allergic reactions [11]. Conversely, fillers formulated with calcium hydroxylapatite (CaHA), such as Radiesse, have a longer-lasting filling period. This can be attributed to the dual mechanism of CaHA fillers, which have the ability to physically add volume while also promoting the stimulation of new collagen. This unique capability of CaHA fillers stems from their biochemical composition, which is similar to the collagen-rich structure of human bone and teeth [12]. Poly-L-lactic acid (PLLA) fillers, such as Sculptra, also aim to promote collagen synthesis, but through a different mechanism of action. PLLA injections increase soft tissue volume by triggering mild inflammatory reactions that eventually lead to the production and deposition of collagen [13]. This is often a gradual process that necessitates up to three treatment sessions to achieve the desired outcome [13]. Therefore, treatment with PLLA is more time-consuming but yields longer-lasting results [14]. The previously discussed fillers are generally categorized as semi-permanent, whereas polymethylmethacrylate (PMMA) is considered a permanent filler. PMMA-based products, such as Bellafill and Artecoll, consist of synthetic microspheres suspended in a collagen carrier gel, designed to promote collagen synthesis over time [15]. Unlike other fillers, PMMA's microspheres are non-biodegradable and remain in the tissue as a scaffold, contributing to its more permanent effects. While the persistence of these microspheres has been associated with a low risk of granuloma formation, PMMA fillers are generally considered to have a good safety profile [8]. One significant risk associated with the use of all fillers is vascular occlusion, a complication that can lead to tissue necrosis or blindness [16]. When selecting a filler, factors such as the desired outcome, treatment area, risk of complications, and longevity should be carefully considered. Fillers are often used to add volume or smooth out static wrinkles, while Botox is commonly used to temporarily freeze the muscles of the face and target dynamic wrinkles. Botox, also known as botulinum toxin, is a neurotoxin derived from the bacteria Clostridium botulinum [17]. When administered, this potent toxin blocks acetylcholine (ACh) release at the neuromuscular junction [18]. Acetylcholine is released by motor neurons to transmit signals that induce muscle contraction. Botox prevents the release of ACh, inhibiting the target muscle from undergoing movement—thereby leading to a temporary paralysis. This "freezing" of small muscles can lead to the diminished appearance of wrinkles, making it a highly sought after aesthetic treatment. Botox is commonly administered to the face—specifically the forehead, glabella, and lateral canthal lines to prevent the formation of wrinkles, or to assist in smoothing out existing ones [19]. In addition to aesthetic applications, Botox is also approved for treatment of conditions such as chronic migraine, cervical dystonia, blepharospasm and strabismus, hyperhidrosis, and bladder dysfunction [20].

3. Ocular Related Complications

Although initially developed by American Ophthalmologist Alan Scott for correcting strabismus and blepharospasm, the use of botulinum toxin has now ex-

panded to include a wide range of both medical and aesthetic indications. Ocular complications from neurotoxins can occur during both medically indicated procedures as well as aesthetic procedures. As reported by Dutton and colleagues, ptosis is the most common complication of botulinum toxin when used for essential blepharospasm. Although ptosis has an average incidence of 13.4%, the reported range was 0 - 52.3% [21]. Ptosis is a condition in which the eyelid droops, sags, and partially obstructs the visual field. Additionally, patients may experience physiological symptoms related to this mechanical dysfunction, such as dry eyes. Botulinum toxin is known to exhibit varying degrees of migration influenced by factors such as dilution, preparation, and the serotype employed. Common adverse events may arise from the diffusion of toxin into the periocular muscles and adjacent areas, such as the levator muscle, lateral canthal region, or lacrimal gland. Notably, the migration of botulinum toxin to the lateral canthal area can lead to incomplete blinking, lagophthalmos, and lower eyelid retraction, which can result in prolonged corneal exposure and contribute to evaporative dry eye disease [22]. Due to their relatively recent introduction to the market, there is limited statistical data available regarding the ocular complications associated with cutaneous fillers. However, it is evident that the use of these products has risen significantly in recent years, and thus, associated complications have followed this trend. In addition to the local transient effects such as bruising, erythema, and swelling, there are potential sight-threatening complications that can occur. Namely, due to their higher viscosity characteristic, dermal fillers are known to cause vaso-occlusive complications. Such complications encompass a range of serious conditions, including ophthalmic artery occlusion, central retinal artery occlusion, ophthalmoplegia, and even stroke. While they are rare, these complications occur for many reasons, including anatomical variation, poor injection technique, and product migration. Shancheng Si and colleagues reported that the severity of complications varied depending on the location of the injection, with the glabella, nasal region, and forehead being the regions associated with a higher risk of severe complications [23]. The glabellar region, situated between the eyebrows and above the nose, is highly vascularized, which increases the risk of vascular compromise during procedures. Importantly, the prominent arterial supply in this area includes the supratrochlear and supraorbital arteries, both of which are branches of the ophthalmic artery. Noteworthy symptoms that may indicate a potential vascular complication include orbital pain, blurred vision, and the sudden onset of dysphotopsias. Recognition of these symptoms plays a key role in early detection and intervention. Khalili and co-authors report on a specific case of optic neuropathy following injection of botulinum toxin A into the left medial rectus muscle [24]. The intended purpose of this procedure was to manage horizontal binocular diplopia. In this particular case, the patient presented with a relatively sudden onset of unilateral blurred vision, limitation of abduction, a positive relative afferent pupillary defect, and dyschromatopsia in his left eye following the procedure. Another case described by Goldberg highlights a case of transient monocular vision

loss with residual temporal field deficit following bilateral lateral rectus muscle botulinum toxin injections for exotropia [25]. In this case, a 22-year-old female with a history of multiple ocular surgeries to correct exotropia presented with gradual and progressive complete visual loss and ptosis of her left eye only hours after injection. Interestingly, this patient had previously undergone this procedure with a successful outcome, resulting in improvement of her exophoria. It is believed that the development of complications following this repeat procedure could in part be due to the patient's altered anatomy because of her previous ocular surgeries. The presumed diagnosis of this case was optic neuropathy based on clinical findings. Ultimately, both patients were treated with a two-week course of oral prednisolone as indicated for the treatment of optic neuropathy. The patient in the first case experienced a complete resolution of symptoms following two weeks of medical therapy, while the patient in the second case reported only partial improvement of symptoms with a remaining deficit of temporal field vision. Significantly, even though these patients received the same treatment, their outcomes were vastly different. This highlights the variation and unpredictability of outcomes regarding adverse effects related to botulinum toxin injection. As discussed previously, complications related to the injection of cutaneous fillers tend to have more vascular adverse events. Zhao and colleagues reveal that events such as skin ischemia, necrosis, ocular and cerebral infarction occur when the hyaluronic acid filler flows backward into the small vasculature supplying the orbit as a result of retrograde embolization [26]. This catastrophic event can lead to sudden vision loss through obstruction of vessels, including the ophthalmic artery and central retinal artery. Attempts to dislodge these emboli and restore visual sensation have been made with the use of intra-articular thrombolytic therapy containing hyaluronidase and vasodilators. While this has been shown to be effective in the improvement of visual acuity, skin necrosis, and skin ecchymosis [27], evidence supporting the notion that this treatment produces consistent positive outcomes remains limited. In conclusion, the ocular manifestations resulting from the adverse effects of botulinum and hyaluronic acid filler injections can severely impact an individual's vision. Given the absence of consistently safe treatment options, it is crucial for patients to be thoroughly informed about the potential risks associated with these procedures.

4. Otolarngology Related Complications

Botulinum toxin has been used in the treatment of many head and neck-related pathologies, including cervical dystonia, chronic migraine, and temporomandibular joint disorders. While this can be an effective treatment modality, it does not come without its own adverse effects. There are several known mechanisms by which botulinum toxin causes unwanted effects, one of which is through diffusion of the toxin to surrounding tissues. The muscles of the neck region are known to have a high susceptibility to toxin diffusion with adverse effects resulting in dysphonia, dysphagia, or dystonia [28]. As reported by Patterson, Dysphagia is the

most common treatment-related adverse effect of botulinum therapy [29]. While this is a rare complication, if it does occur, careful consideration should be taken to prevent serious clinical scenarios such as malnutrition or dehydration. A cohort study involving 209 children examined the adverse effects of botulinum toxin injection following treatment for drooling. Difficulty swallowing, eating, drinking, and articulating were among the complications observed in this study. The duration of adverse events can vary depending on patient specific variables including metabolism and muscle density in addition to the injection technique used by the clinician. Fortunately, most of the events reported from this study were transient with approximately 54% resolving after four weeks [30]. More severe complications have been seen following injection of botulinum toxin for the treatment of spasmodic dysphonia, a vocal disorder caused by involuntary contractions of muscles in the larynx. Acute airway obstruction requiring intubation is a life-threatening complication that can occur when using botulinum toxin for chemodenervation of laryngeal muscles, as indicated in the current standard of therapy for adductor spasmodic dysphonia [31]. As reported by Yershov et al., a patient in this clinical scenario requires treatment with nebulized adrenaline and intravenous hydrocortisone to reduce airway inflammation and improve symptoms of stridor [32]. As seen with ocular complications, cutaneous fillers commonly cause vascular occlusions in the nasal region. With the interest in instant gratification, there has been increased interest in non-surgical rhinoplasty procedures in recent years. Alongside this trend, there has been a presumably notable rise in vascular complications, attributed to the complex vascular anatomy of the nasal region. Despite having a relatively high safety profile, hyaluronic acid filler has been associated with serious vascular injuries leading to permanent cutaneous scarring [33]. When hyaluronic acid fillers are injected by individuals with inadequate training, there is a potential for devastating adverse events secondary to failure to recognize the signs of injury at an early stage, in addition to inadequate knowledge of anatomical vasculature. It is important to understand the defining timeline of symptom onset in the setting of vascular complications, with pain and blanching being two symptoms that may occur within seconds following the injection of filler into an artery. Additional signs that may manifest within several minutes following intra-arterial injection include a livedo pattern, delayed capillary refill time, or a dusky appearance of regional skin. The final and most severe symptom is skin breakdown, which occurs as opportunistic anaerobic infections predominate in tissues lacking an oxygen supply [34]. Several avenues to restore blood supply may be initiated during times of complication, including decompression therapy, hyperbaric oxygen therapy, antibiotics, and vasodilating therapy in combination with supportive care. Despite efforts to control the damage caused by vascular occlusion, some patients may experience widespread and notable scarring related to cutaneous necrosis [35]. Similarly to vascular occlusions in the ocular region, the use of intra-arterial thrombolytic therapy consisting of a combination of hyaluronidase, urokinase, and vasodilator may be employed to promote

reperfusion of tissue. Interestingly, the method by which hyaluronidase is administered has been shown to alter the outcome of this treatment. High-dose pulse administration of hyaluronidase has been reported to have improved outcomes, specifically in the setting of skin necrosis [36]. Hyperbaric oxygen therapy is a unique therapeutic modality that has been introduced as a complementary therapy for vascular occlusive events. Through a variety of different mechanisms, hyperbaric oxygen therapy is theorized to improve oxygenation of ischemic tissues, reduce edema, and promote angiogenesis and collagen formation. However, the efficacy of its use in this clinical scenario is unknown [37]. Ultimately, clinician expertise and patient education regarding alarming symptoms are crucial for the prevention, early diagnosis, and management of these vascular complications.

5. Risk Factors for Complications

5.1. Patient-Related Factors

1) Anatomical Variations

Anatomical variations are a critical consideration in the administration of HA dermal fillers and botulinum injections. The distribution of fat, skin thickness, and the underlying musculature all vary from patient to patient, which can significantly affect how the filler is absorbed and settled. For example, some patients may have a naturally thinner skin layer in certain areas of their face, making them more prone to filler migration and visibility of lumps or irregularities after the procedure [16]. Certain areas of the face are particularly prone to complications due to their complex vascular networks. High-risk zones, such as the glabella (area between the eyebrows), the nasal ala (the outer edge of the nostrils), and the forehead, contain numerous blood vessels and are more likely to experience adverse events such as ischemia, necrosis, or vascular occlusion if injected improperly [38]. These areas require extra caution, as filler injections can easily block blood flow, leading to tissue damage and severe complications. Therefore, understanding the patient's unique facial anatomy and adapting injection techniques accordingly is vital for minimizing risks. Another example of anatomical variation includes patients with asymmetry in their facial structures, such as a stronger or weaker side of the face, which can influence the even distribution of the filler. Misjudging these variations or failing to account for them during treatment can lead to uneven results or complications such as product migration, which may necessitate corrective procedures [16].

2) Pre-existing Conditions

Several pre-existing medical conditions can elevate the risk of complications with HA dermal filler procedures. Patients with autoimmune diseases (e.g., lupus, rheumatoid arthritis) are more prone to hypersensitivity reactions, either immediately after the injection or as delayed responses [39]. These reactions can range from localized swelling and redness to more severe manifestations such as granulomas or tissue necrosis [39]. Therefore, a thorough review of the patient's medical history is essential before proceeding with treatment to identify such risks. Pa-

tients with poor circulation, especially those with vascular disorders like a history of deep vein thrombosis (DVT) or peripheral arterial disease (PAD), are at higher risk for tissue ischemia and necrosis, particularly in areas of the face with reduced blood supply. Vascular occlusion is one of the most severe complications associated with HA filler injections and can lead to permanent tissue damage or scarring if not recognized and treated promptly [40]. Therefore, injectors should be cautious when working on high-risk regions like the glabella or the nose, where blood flow may be more compromised. Similarly, dermatological conditions such as eczema, rosacea, and psoriasis can result in compromised skin integrity, which increases the likelihood of infection or excessive inflammatory responses after filler injections. The use of fillers in compromised skin can exacerbate irritation, leading to infections, severe swelling, or the formation of abscesses, which may require antibiotics or even surgical drainage to resolve [40]. A careful assessment of the patient's skin health is crucial to reduce these risks. Medications such as anticoagulants (e.g., warfarin, aspirin) and immunosuppressants (e.g., corticosteroids) are common among patients and can significantly affect the healing process and the likelihood of complications. Anticoagulants increase the risk of prolonged bruising and bleeding at the injection site, while immunosuppressants reduce the body's ability to fight infections, making patients more susceptible to post-procedure infections [41]. These patients may also experience delayed healing or increased swelling. A careful evaluation of their medication history is essential before proceeding with treatment.

5.2. Provider-Related Factors

Experience and Training

The skill and experience of the injector are perhaps the most important factors in reducing the risk of adverse events during HA filler procedures. Inexperienced injectors are more likely to use improper injection techniques, such as injecting too much filler in a single area or at an incorrect depth, which can lead to overfilling, visible lumps, or irregular contours on the face [42]. Overfilling, which occurs when excessive amounts of filler are introduced into a single region, can cause unnatural or exaggerated facial features, leading to patient dissatisfaction and the need for corrective procedures like hyaluronidase injections or surgical revision [42]. More severe complications such as vascular occlusion are directly linked to improper injection techniques. Vascular occlusion occurs when the injected filler inadvertently enters or compresses a blood vessel, blocking blood flow to the affected area. This blockage can cause ischemia, tissue necrosis, or ulceration, requiring immediate medical intervention to avoid permanent tissue damage [43]. Injectors must have advanced knowledge of facial anatomy, particularly the vascular system, to avoid injecting into or near blood vessels. Therefore, an in-depth understanding of facial anatomy, as well as the ability to adapt to each patient's specific needs, is essential to prevent these complications. The injector's choice of injection technique is also critical in reducing the risk of more serious complications such as blindness, which can result from vascular embolization into the oph-

thalmic artery. This rare but severe complication has been linked to high injection pressures, the use of improper needles or cannulas, and filler placement in high-risk zones. To minimize the risk, skilled injectors are trained to use smaller, blunt needles or cannulas and avoid high-pressure injections, particularly in sensitive areas like the periorbital region [38]. Aspiration before injection to confirm the absence of blood vessels and using a slower, more controlled injection technique can also help reduce the risk of vascular embolization. Beyond technical skills, the experience of the provider also extends to their ability to assess the patient's needs and suitability for filler treatments. An experienced injector will carefully consider the patient's goals, anatomy, and medical history to determine the most appropriate approach. This includes considering factors such as the patient's expectations, as misaligned expectations can lead to dissatisfaction and, in some cases, complications related to over-correction or under-correction of aesthetic concerns [44]. Additionally, experienced injectors take time to educate their patients about the potential risks, signs of complications, and the importance of seeking prompt medical attention if any issues arise post-procedure. Risk factors for complications with HA dermal fillers are multifactorial, involving both patient-specific factors and provider-related factors. Patient anatomical variations, pre-existing medical conditions, and medications play significant roles in determining the likelihood of complications, while the skill and experience of the provider are critical to ensuring safe and effective outcomes. Skilled injectors must thoroughly assess each patient's medical history and unique facial anatomy, and employ appropriate techniques to minimize risks like overfilling, vascular occlusion, and infections. By focusing on patient safety, skilled providers can reduce the potential for adverse events and enhance the overall success of HA dermal filler treatments.

6. Measures to Prevent Complications

Preventing ocular and ENT complications from cutaneous filler and Botox injections begins with a strong foundation in anatomy, proper patient selection, and meticulous technique. Practitioners must have a thorough understanding of the vascular supply to the face, particularly high-risk zones such as the glabella, nasolabial fold, and periorbital regions, to avoid inadvertent intravascular injection. The use of blunt cannulas instead of sharp needles, aspiration before injection, and the limitation of injection volume can further reduce the risk of embolic events [45] [46]. Ultrasound-guided injections are also emerging as a tool to enhance safety in complex or high-risk areas [47]. Adherence to precise injection techniques and anatomical landmarks remains essential to reducing the risk of serious vascular complications. In addition to technical precautions, patient education and informed consent are key components of prevention. Patients should be counseled on both common and rare complications, and signs of vision loss, diplopia, or ENT symptoms like sudden hearing changes or facial swelling should be reviewed as red flags that warrant immediate evaluation. Early recognition and prompt intervention, such as administering hyaluronidase for hyaluronic acid

filler complications, can dramatically improve outcomes [48]. Practitioners should also be trained to recognize vascular occlusion early, including subtle skin changes like blanching or mottling, and be prepared to implement standardized emergency protocols [48]. Ultimately, empowering patients with knowledge and clinicians with intervention protocols can significantly mitigate the severity of adverse events. Finally, ongoing training, adherence to evidence-based guidelines, and the use of simulation or cadaver-based injection courses can help ensure that injectors are equipped to practice safely. Many serious complications are iatrogenic and preventable; thus, fostering a culture of continual learning and risk awareness is essential. As demand for minimally invasive procedures grows, so too must the emphasis on safety, precision, and preparation to minimize harm and preserve patient trust [49]. Continued education and professional accountability are vital to maintaining safety standards as cosmetic procedures become increasingly widespread.

7. Conclusion

Modifying appearance and changing functionality of the face through use of filler and botulinum toxin is commonplace. Patient and provider understanding of complications establishes higher standards for administration and avoidance of serious effects. An ultrasound guided injection technique can be used to enhance accuracy of cosmetic injection procedures and minimize adverse events by providing precise visualization of facial anatomy. Adhering to strict anatomical landmarks increases patient safety as the vascular structures in the periocular, nasal, and cervical regions require meticulous technique to minimize risks. Recognition and management of immediate adverse effects like evidence of vascular occlusion, erythema, and blanching can allow for prompt implementation of emergency protocols leading to improved outcomes. Use of hyaluronidase to dissolve filler can offer immediate reversal. Severe outcomes such as ophthalmoplegia, diplopia, or vision loss are extremely rare. Options for intensive treatment like hyperbaric oxygen therapy can help to preserve vision. Collaborative treatment between ophthalmologists, otolaryngologists, vascular surgeons, and dermatologists can help improve patient safety by monitoring adverse effects as a team approach. The cross-disciplinary creation of supplemental modules can significantly enhance the education of providers by enhancing the comprehension of anatomical structures and vascular paths, and optimizing their injection skills, through targeted, continuing education experiences. Future studies on methods of office and clinic management to allow for such interdisciplinary care can improve more prompt management when adverse effects occur in outpatient settings. Additionally, further study of how to seamlessly implement procedures that utilize hyperbaric oxygen methods can improve accessibility, further understanding of supporting angiogenesis, and later reach a direction of cost reduction if serious complications need to be prevented through this route. Ultimately, a goal of creating facial harmony and minimizing complications while achieving ideal aesthetic and therapeutic

outcomes is needed to best support patients and practitioners.

Conflicts of Interest

The authors declare no conflicts of interest regarding the publication of this paper.

References

[1] Trinh, L.N. and Gupta, A. (2021) Non-Hyaluronic Acid Fillers for Midface Augmentation: A Systematic Review. *Facial Plastic Surgery*, **37**, 536-542. https://doi.org/10.1055/s-0041-1725164

[2] Kumar, R., Dhaliwal, H., Kukreja, R. and Singh, B. (2016) The Botulinum Toxin as a Therapeutic Agent: Molecular Structure and Mechanism of Action in Motor and Sensory Systems. *Seminars in Neurology*, **36**, 10-19. https://doi.org/10.1055/s-0035-1571215

[3] Borba, A., Matayoshi, S. and Rodrigues, M. (2021) Avoiding Complications on the Upper Face Treatment with Botulinum Toxin: A Practical Guide. *Aesthetic Plastic Surgery*, **46**, 385-394. https://doi.org/10.1007/s00266-021-02483-1

[4] Ferrari, A. (2018) Pharmacological Differences and Clinical Implications of Various Botulinum Toxin Preparations: A Critical Appraisal. *Functional Neurology*, **33**, 7-18. https://doi.org/10.11138/fneur/2018.33.1.007

[5] Li, X., Sui, C., Xia, X. and Chen, X. (2022) Efficacy and Safety of Botulinum Toxin Type A for Treatment of Glabellar Lines: A Network Meta-Analysis of Randomized Controlled Trials. *Aesthetic Plastic Surgery*, **47**, 365-377. https://doi.org/10.1007/s00266-022-03018-y

[6] Jia, Z., Lu, H., Yang, X., Jin, X., Wu, R., Zhao, J., *et al.* (2016) Adverse Events of Botulinum Toxin Type a in Facial Rejuvenation: A Systematic Review and Meta-analysis. *Aesthetic Plastic Surgery*, **40**, 769-777. https://doi.org/10.1007/s00266-016-0682-1

[7] Li, Z., Yang, Y., Yu, N., Zhou, W., Li, Z., Chong, Y., *et al.* (2021) The "Visible" Muscles on Ultrasound Imaging Make Botulinum Toxin Injection More Precise: A Systematic Review. *Aesthetic Plastic Surgery*, **46**, 406-418. https://doi.org/10.1007/s00266-021-02493-z

[8] Guo, J., Fang, W. and Wang, F. (2023) Injectable Fillers: Current Status, Physicochemical Properties, Function Mechanism, and Perspectives. *RSC Advances*, **13**, 23841-23858. https://doi.org/10.1039/d3ra04321e

[9] Sánchez-Carpintero, I., Candelas, D. and Ruiz-Rodríguez, R. (2010) Dermal Fillers: Types, Indications, and Complications. *Actas Dermo-Sifiliográficas* (*English Edition*), **101**, 381-393. https://doi.org/10.1016/s1578-2190(10)70660-0

[10] Go, B.C., Frost, A.S. and Friedman, O. (2023) Using Injectable Fillers for Chin and Jawline Rejuvenation. *World Journal of Otorhinolaryngology—Head and Neck Surgery*, **9**, 131-137. https://doi.org/10.1002/wjo2.93

[11] Baumann, L. (2006) Collagen-Containing Fillers: Alone and in Combination. *Clinics in Plastic Surgery*, **33**, 587-596. https://doi.org/10.1016/j.cps.2006.08.001

[12] Loghem, J.V., Yutskovskaya, Y.A. and Werschler, W.P. (2015) Calcium Hydroxylapatite: Over a Decade of Clinical Experience. *The Journal of Clinical and Aesthetic Dermatology*, **8**, 38-49. https://pmc.ncbi.nlm.nih.gov/articles/PMC4295857/

[13] Pavicic, T. and Funt, D. (2013) Dermal Fillers in Aesthetics: An Overview of Adverse Events and Treatment Approaches. *Clinical, Cosmetic and Investigational Dermatology*, **6**, 295-316. https://doi.org/10.2147/ccid.s50546

[14] Bauer, U. and H Graivier, M. (2011) Optimizing Injectable Poly-L-Lactic Acid Administration for Soft Tissue Augmentation: The Rationale for Three Treatment Sessions. *Canadian Journal of Plastic Surgery*, **19**, 22-27. https://doi.org/10.1177/229255031101900311

[15] Haneke, E. (2004) Polymethyl Methacrylate Microspheres in Collagen. *Seminars in Cutaneous Medicine and Surgery*, **23**, 227-232. https://doi.org/10.1016/j.sder.2004.08.002

[16] Signorini, M., Liew, S., Sundaram, H., De Boulle, K.L., Goodman, G.J., Monheit, G., *et al.* (2016) Global Aesthetics Consensus: Avoidance and Management of Complications from Hyaluronic Acid Fillers—Evidence- and Opinion-Based Review and Consensus Recommendations. *Plastic & Reconstructive Surgery*, **137**, 961e-971e. https://doi.org/10.1097/prs.0000000000002184

[17] Biello, A. and Zhu, B. (2023) Botulinum Toxin Treatment of the Upper Face. StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK574523/

[18] Brin, M.F. and Burstein, R. (2023) Botox (Onabotulinumtoxina) Mechanism of Action. *Medicine*, **102**, e32372. https://doi.org/10.1097/md.0000000000032372

[19] Nguyen, T.T. (2020) Plastic Surgery and Cosmetic Procedures: Facial Injection Procedures. *FP Essentials*, **497**, 11-17. https://pubmed.ncbi.nlm.nih.gov/33021773/#:~:text=The%20facial%20areas%20in%20which,used%20filler%20and%20is%20hypoallergenic)

[20] Padda, I.S. and Tadi, P. (2023) Botulinum Toxin. StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK557387/

[21] Dutton, J.J. and Fowler, A.M. (2007) Botulinum Toxin in Ophthalmology. *Survey of Ophthalmology*, **52**, 13-31. https://doi.org/10.1016/j.survophthal.2006.10.003

[22] Nagendran, S.T., Ali, M.J., Dogru, M. and Malhotra, R. (2022) Complications and Adverse Effects of Periocular Aesthetic Treatments. *Survey of Ophthalmology*, **67**, 741-757. https://doi.org/10.1016/j.survophthal.2021.04.009

[23] Si, S., Lai, L., Ding, X., Su, W., Zhou, G., Wang, Q., *et al.* (2022) A New Injury Severity Scale for Ocular Complications Following Cosmetic Filler Injection. *Frontiers in Bioscience-Landmark*, **27**, Article 59. https://doi.org/10.31083/j.fbl2702059

[24] Reza Khalili, M., Hosseini, S., Shirvani, M. and Sadat Sadati, M. (2022) Optic Neuropathy Following Botulinum Toxin Injection into the Medial Rectus Muscle for Diplopia. *Journal of Ophthalmic and Vision Research*, **17**, 296-302. https://doi.org/10.18502/jovr.v17i2.10806

[25] Goldberg, A., Botcherby, E. and Maling, S. (2024) Case Report: Visual Field Loss Following Lateral Rectus Muscle Botulinum Toxin Injection. *Clinical Case Reports and Studies*, **5**, 1-4. https://doi.org/10.59657/2837-2565.brs.24.097

[26] Zhao, F., Chen, Y., He, D., You, X. and Xu, Y. (2024) Disastrous Cerebral and Ocular Vascular Complications after Cosmetic Facial Filler Injections: A Retrospective Case Series Study. *Scientific Reports*, **14**, Article No. 3495. https://doi.org/10.1038/s41598-024-54202-w

[27] Xu, X., Zhou, G., Fu, Q., Zhang, L., Yu, Y., Dong, Y., *et al.* (2021) Efficacy of Intra-arterial Thrombolytic Therapy for Vision Loss Resulting from Hyaluronic Acid Filler Embolization. *Journal of Cosmetic Dermatology*, **20**, 3205-3212. https://doi.org/10.1111/jocd.14111

[28] Witmanowski, H. and Błochowiak, K. (2020) The Whole Truth about Botulinum Toxin—A Review. *Advances in Dermatology and Allergology*, **37**, 853-861. https://doi.org/10.5114/ada.2019.82795

[29] Patterson, A., Almeida, L., Hess, C.W., Martinez-Ramirez, D., Okun, M.S., Rodriguez, R.L., *et al.* (2016) Occurrence of Dysphagia Following Botulinum Toxin Injection in Parkinsonism-Related Cervical Dystonia: A Retrospective Study. *Tremor and Other Hyperkinetic Movements*, **6**, Article 379. https://doi.org/10.5334/tohm.285

[30] van Hulst, K., Kouwenberg, C.V., Jongerius, P.H., Feuth, T., van den Hoogen, F.J.A., Geurts, A.C.H., *et al.* (2016) Negative Effects of Submandibular Botulinum Neurotoxin A Injections on Oral Motor Function in Children with Drooling Due to Central Nervous System Disorders. *Developmental Medicine & Child Neurology*, **59**, 531-537. https://doi.org/10.1111/dmcn.13333

[31] Schuering, J.H.C., Heijnen, B.J., Sjögren, E.V. and Langeveld, A.P.M. (2019) Adductor Spasmodic Dysphonia: Botulinum Toxin A Injections or Laser Thyroarytenoid Myoneurectomy? A Comparison from the Patient Perspective. *The Laryngoscope*, **130**, 741-746. https://doi.org/10.1002/lary.28105

[32] Yershov, D. and Partridge, R. (2020) Life Threatening Delayed Complication of Botulinum Toxin Injection for Treatment of Spasmodic Dysphonia. *Prague Medical Report*, **121**, 114-117. https://doi.org/10.14712/23362936.2020.10

[33] Ehlinger-David, A., Gorj, M., Braccini, F., Loreto, F., Grand-Vincent, A., Garcia, P., *et al.* (2022) A Prospective Multicenter Clinical Trial Evaluating the Efficacy and Safety of a Hyaluronic Acid-based Filler with Tri-Hyal Technology in the Treatment of Lips and the Perioral Area. *Journal of Cosmetic Dermatology*, **22**, 464-472. https://doi.org/10.1111/jocd.15169

[34] King, M., Walker, L., Convery, C. and Davies, E. (2020) Management of a Vascular Occlusion Associated with Cosmetic Injections. *The Journal of Clinical and Aesthetic Dermatology*, **13**, E53-E58.

[35] Chen, Q., Liu, Y. and Fan, D. (2016) Serious Vascular Complications after Nonsurgical Rhinoplasty: A Case Report. *Plastic and Reconstructive Surgery—Global Open*, **4**, e683. https://doi.org/10.1097/gox.0000000000000668

[36] Germani, M., Alegria, P., Giro, G. and Munoz-Lora, V.R.M. (2024) High-Dose Pulsed Hyaluronidase for Managing Nasal Skin Necrosis Following Hyaluronic Acid Treatment in Nasolabial Folds: A Case Report. *Journal of Oral Biology and Craniofacial Research*, **14**, 339-341. https://doi.org/10.1016/j.jobcr.2024.04.006

[37] Henderson, R., Reilly, D.A. and Cooper, J.S. (2018) Hyperbaric Oxygen for Ischemia Due to Injection of Cosmetic Fillers: Case Report and Issues. *Plastic and Reconstructive Surgery—Global Open*, **6**, e1618. https://doi.org/10.1097/gox.0000000000001618

[38] Egbert, J.E. (2001) High Injection Pressure during Intralesional Injection of Corticosteroids into Capillary Hemangiomas. *Archives of Ophthalmology*, **119**, 677-683. https://doi.org/10.1001/archopht.119.5.677

[39] Goodman, G.J., Liew, S., Callan, P. and Hart, S. (2020) Facial Aesthetic Injections in Clinical Practice: Pretreatment and Posttreatment Consensus Recommendations to Minimise Adverse Outcomes. *Australasian Journal of Dermatology*, **61**, 217-225. https://doi.org/10.1111/ajd.13273

[40] Kalmanson, O.A., Misch, E.S. and Terella, A. (2022) Hyaluronic Acid Fillers May Be Longer-Lasting than Previously Described: A Case Report of Delayed Filler-Associated Facial Cellulitis. *JPRAS Open*, **33**, 37-41. https://doi.org/10.1016/j.jpra.2022.05.011

[41] Amaraneni, A., Chippa, V., Goldin, J., *et al.* (2024) Anticoagulation Safety. StatPearls. https://www.ncbi.nlm.nih.gov/books/NBK519025/

[42] Park, T., Seo, S., Kim, J. and Chang, C. (2011) Clinical Experience with Hyaluronic Acid-Filler Complications. *Journal of Plastic, Reconstructive & Aesthetic Surgery*, **64**, 892-896. https://doi.org/10.1016/j.bjps.2011.01.008

[43] Kyriazidis, I., Spyropoulou, G., Zambacos, G., Tagka, A., Rakhorst, H.A., Gasteratos, K., *et al.* (2023) Adverse Events Associated with Hyaluronic Acid Filler Injection for Non-Surgical Facial Aesthetics: A Systematic Review of High Level of Evidence Studies. *Aesthetic Plastic Surgery*, **48**, 719-741. https://doi.org/10.1007/s00266-023-03465-1

[44] De Boulle, K. and Heydenrych, I. (2015) Patient Factors Influencing Dermal Filler Complications: Prevention, Assessment, and Treatment. *Clinical, Cosmetic and Investigational Dermatology*, **8**, 205-214. https://doi.org/10.2147/ccid.s80446

[45] Beleznay, K., Carruthers, J.D.A., Humphrey, S. and Jones, D. (2015) Avoiding and Treating Blindness from Fillers: A Review of the World Literature. *Dermatologic Surgery*, **41**, 1097-1117. https://doi.org/10.1097/dss.0000000000000486

[46] Lazzeri, D., Agostini, T., Figus, M., Nardi, M., Pantaloni, M. and Lazzeri, S. (2012) Blindness Following Cosmetic Injections of the Face. *Plastic and Reconstructive Surgery*, **129**, 995-1012. https://doi.org/10.1097/prs.0b013e3182442363

[47] Scheuer, J.F., Sieber, D.A., Pezeshk, R.A., Campbell, C.F., Gassman, A.A. and Rohrich, R.J. (2017) Anatomy of the Facial Danger Zones: Maximizing Safety during Soft-Tissue Filler Injections. *Plastic & Reconstructive Surgery*, **139**, 50e-58e. https://doi.org/10.1097/prs.0000000000002913

[48] Cohen, J.L., Biesman, B.S., Dayan, S.H., DeLorenzi, C., Lambros, V.S., Nestor, M.S., *et al.* (2015) Treatment of Hyaluronic Acid Filler-Induced Impending Necrosis with Hyaluronidase: Consensus Recommendations. *Aesthetic Surgery Journal*, **35**, 844-849. https://doi.org/10.1093/asj/sjv018

[49] Haneke, E. (2015) Managing Complications of Fillers: Rare and Not-So-Rare. *Journal of Cutaneous and Aesthetic Surgery*, **8**, 198-210. https://doi.org/10.4103/0974-2077.172191